---
schema_version: "secwatch.filing_event.v1"
accession: "0001824293-23-000018"
form_type: "8-K"
ticker: "GRI"
cik: "0001824293"
company_name: "GRI Bio, Inc."
filed_at: "2023-02-24T23:59:59+00:00"
generated_at: "2026-06-19T00:54:08.443701+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vallon Pharma reports FY2022 net loss of $7.0M; merges with GRI Bio in all-stock deal

## Summary
- Net loss of $7.0M for FY2022 vs. $9.3M in FY2021; R&D expenses fell to $1.2M from $5.2M.
- Cash and cash equivalents of $3.8M as of Dec 31, 2022.
- Definitive merger agreement with GRI Bio: all-stock transaction; combined company to operate as GRI Bio, Inc. under ticker 'GRI'.
- Merger expected to close in Q2 2023; focus on NKT cell regulators for inflammatory, fibrotic and autoimmune diseases.
- G&A expenses rose to $5.8M from $4.1M due to evaluation of strategic alternatives.

## SEC filing metadata
- accession: 0001824293-23-000018
- form_type: 8-K
- ticker: GRI
- cik: 0001824293
- company_name: GRI Bio, Inc.
- filed_at: 2023-02-24T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824293/000182429323000018/0001824293-23-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824293/000182429323000018/val-20230224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001824293-23-000018
- JSON: https://secwatch.observer/filing/0001824293-23-000018.json
- Plain text: https://secwatch.observer/filing/0001824293-23-000018.txt

## Key facts
- Earnings Releases
  GRI Bio, Inc. reported the fiscal year ended December 31, 2022 results: net income $7.0 million.
  - Period: the fiscal year ended December 31, 2022
  - Net income: $7.0 million
  - Result: reported results
  source text: Vallon Pharmaceuticals Reports Fiscal Year 2022 Financial Results PHILADELPHIA, PA, February 24, 2023 – Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), today reported its financial results for the fiscal year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1824293/000182429323000018/0001824293-23-000018-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.